Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment

British Journal of Cancer

Volumn 86, Issue 3, 2002, Pages 402-408

  Michalides, R ^a   Van Tinteren, H ^a,c   Balkenende, A ^a   Vermorken, J B ^b   Benraadt, J ^c   Huldij, J ^c   Van Diest, P ^d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c Integraal Kankercentrum Amsterdam   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cell cycle markers; Cyclin A; Cyclin D I; Human breast cancer; Prognosis; Tamoxifen

Indexed keywords

CYCLIN A; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL CYCLE; CYCLIN A; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; SURVIVAL RATE; TAMOXIFEN; TIME FACTORS;

EID: 0036473059     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600072     Document Type: Article

References (50)

1. cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G1 arrested human breast cancer cells
2. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
3. Cyclin D1 gene amplification and expression in breast carcinoma: Relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21(WAF1) immunohistochemical expression
4. Kip1 expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up
5. Ectopic expression of cdc25A accelerates the G1/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases
6. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene
7. Pathogenesis of estrogen-receptor positive and -negative breast cancer
8. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast cancer
9. Role of the Cdc25A phosphatase in human breast cancer
10. Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells
11. Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D)
12. The antiestrogen ICI 182, 780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion
13. Concerted over-expression of the genes encoding p21 and cyclin D1 is associated with growth inhibition and differentiation in various carcinomas
14. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitine-protea-some pathway
15. Tamoxifen for early breast cancer: An overview of randomised trials
16. Pathology and breast cancer screening
17. Five versus more than five years of tamoxifen for lymph-node negative breast cancer: Updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial
18. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells
19. Multifaceted regulation of cell cycle progression by estrogen: Regulation of cdk inhibitors and Cdc25A independent of cyclin D1-cdk4 function
20. Cdc25 phosphatases as potential human oncogenes
21. Cyclin D1 and prognosis
22. Overexpression of c-erBb2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
23. Cdc25A is a novel phosphatase functioning early in the cell cycle
24. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor -positive breast cancer
25. Regulation between the functional interaction between cyclin D1 and the estrogen receptor
26. Cell cycle proteins do not predict outcome in grade 1 infiltrating ductal carcinoma of the breast
27. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer
28. Cell cycle regulators: Mechanisms and their role in aetiology, prognosis, and treatment of cancer
29. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell progression
30. G1-S transition defects occur in most breast cancers and predict outcome
31. Selective estrogen receptor tranlators: Structure, function, and clinical use
32. Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens
33. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution
34. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin ECdk2
35. 1 phase in rodent fibroblasts
36. Estrogen and progesterone receptors in normal female breast
37. Expression of cydin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia
38. Potentiation of human estrogen receptor α transcriptional activation through phosphorylation of serines 104 and 106 by the cyclinA-cdl2 complex
39. Estrogen induction of cyclin D1 promoter: Involvement of a cAMP response-like element
40. 1-phase progression
41. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
42. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer
43. Scottish Adjuvant Tamoxifen Trial: A randomized study updated to 15 years
44. Cyclin D1 expression in invasive breast cancer, correlations and prognostic value
45. Adjuvant tamoxifen in breast cancer: Interim results of a comprehensive cancer center Amsterdam trial
46. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
47. Tamoxifen and other antiestrogens in prevention and therapy of breast cancer
48. Cdk-independent activation of estrogen receptor by cydin D1
49. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1